aldometanib

Aldometanib (LXY-05-029) is an orally active small molecule inhibitor of the glycolytic enzyme aldolase. By preventing fructose 1,6-bisphosphate (FBP) from binding to v-ATPase-associated aldolase, it selectively activates lysosomal adenosine monophosphate–activated protein kinase (AMPK), mimicking a cellular state of glucose starvation. This activation leads to decreased blood glucose levels and has beneficial metabolic effects in preclinical models, including reduction of fatty liver and nonalcoholic steatohepatitis in obese rodents. Aldometanib elicits an insulin-independent glucose-lowering effect without causing hypoglycemia and has been shown to extend lifespan and healthspan in animal studies. It is primarily used for research into metabolic homeostasis[1][2][3].

Other names

aldometanibLXY-05-029LXY05-029LXY 05-029